Specialized in R&D of new anti-infective drugs, Nosopharm is currently open to industrial and academic partnerships to pursue development of innovative pipeline to fight antibiotic resistance.
Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces that it has been selected for the new French Tech Health20 program. The class of 2023 includes 21 innovative French companies in biotech, medtech and digital health.
The French Tech Health20 initiative supports high-potential French start-ups that meet a common objective: accelerating innovation to help France gain technological, industrial and health sovereignty. It will support these start-ups in their development and scaling-up. It covers the ‘Health Innovation 2030’ priority areas, in close collaboration with the French Health Innovation Agency. Selection was based on the criteria of economic and technological potential.